HIROHITO SEKI

Dr. HIROHITO SEKI


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2024 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
SSShinsuke Sasada
Shinsuke Sasada
NNNaomi Nagura
Naomi Nagura
ASAyaka Shimo
Ayaka Shimo
AOAkiko Ogiya
Akiko Ogiya
MSMiho Saiga
Miho Saiga
Tadahiko ShienTadahiko Shien
Tadahiko Shien

28 June 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
THTetsu Hayashida
Tetsu Hayashida
HJHiromitsu Jinno
Hiromitsu Jinno
KMKatsuaki Mori
Katsuaki Mori
HSHiroki Sato
Hiroki Sato
AMAkira Matsui
Akira Matsui
YKYuko Kitagawa
Yuko Kitagawa
Eribulin mesylate is currently indicated as a sequential monotherapy to be administered after two chemotherapeutic regimens, including anthracycline and taxane treatments, for treatment of metastatic breast cancer. This open-label, multicenter phase II study was designed to evaluate the efficacy and safety of eribulin as a first- or second-line treatment for patients with metastatic breast cancer. The primary objective was to determine the overall response rate. Secondary objectives were to evaluate progression-free survival and the safety profile. Patients were scheduled to receive eribulin mesylate 1.4 mg/m2 intravenously on days 1 and 8 of a 21-day cycle. Patients received the study treatment unless disease progression, unacceptable toxicity, or a request to discontinue from the patient and/or investigator eventuated. Between December 2012 and September 2015, 32 patients with metastatic breast cancer were enrolled at 10 participating clinical institutions in Japan, and toxicity and response rates were evaluated. The overall response rate was 43.8% (95% confidence interval [CI] 26.5–61.0). The clinical benefit and tumor control rates were 56.3% (95% CI 39.0–73.5) and 78.1% (95% CI 63.8–92.5), respectively. Median progression-free survival was 8.3 months (95% CI 7.1–9.4). A subgroup analysis did not identify any factors affecting the efficacy of eribulin. The most common adverse events were neutropenia (71.9%), alopecia (68.7%), and peripheral neuropathy (46.9%). As a first- or second-line therapy, eribulin showed sufficient efficacy for metastatic breast cancer compared with taxane and capecitabine treatment in previous clinical trials. The safety profile of eribulin was acceptable. Eribulin may be another option for first-line chemotherapeutic regimens for metastatic breast cancer. This trial was retrospectively registered at the University Hospital Medical Information Network (UMIN) Clinical Trial Registry (ID number: UMIN000010334 ). Date of trial registration: April 1st, 2013.

8 June 2019 in Breast Cancer
Verified
Journal Article
Closed access
PDF file
HSHIROHITO SEKI
HIROHITO SEKI
TSTakashi Sakurai
Takashi Sakurai
SMShodai Mizuno
Shodai Mizuno
TTToshiki Tokuda
Toshiki Tokuda
TKTakuji Kaburagi
Takuji Kaburagi
HJHiromitsu Jinno
Hiromitsu Jinno

12 February 2020 in Surgery Today
Verified
Journal Article
Closed access
PDF file
HSHIROHITO SEKI
HIROHITO SEKI
TSTakashi Sakurai
Takashi Sakurai
YMYuka Maeda
Yuka Maeda
NONaohiko Oki
Naohiko Oki
MAMina Aoyama
Mina Aoyama
KSKen Shimizu
Ken Shimizu

19 June 2024 in Breast Cancer
Verified
Journal Article
Closed access
PDF file
HSHIROHITO SEKI
HIROHITO SEKI
AOAkiko Ogiya
Akiko Ogiya
NNNaomi Nagura
Naomi Nagura
ASAyaka Shimo
Ayaka Shimo
KNKazutaka Narui
Kazutaka Narui
CSCollaborative Study Group of Scientific Research of the Japanese Breast Cancer Society
Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society

29 October 2019 in In Vivo
Verified
Journal Article
Closed access
PDF file
HSHIROHITO SEKI
HIROHITO SEKI
TSTakashi Sakurai
Takashi Sakurai
YMYuka Maeda
Yuka Maeda
NONaohiko Oki
Naohiko Oki
MAMina Aoyama
Mina Aoyama
KSKen Shimizu
Ken Shimizu
Background/Aim: Published data have shown that palbociclib-fulvestrant can significantly improve the progression-free survival (PFS) of estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2−) metastatic breast cancer patients, but not of Japanese patients. We conducted this retrospective study to verify the efficacy and safety of palbociclib-fulvestrant in Japanese patients. Patients and Methods: ER+/HER2− metastatic breast cancer patients treated with fulvestrant (n=39) or palbociclib-fulvestrant (n=31) at the Saitama Medical Center from July 2012 to November 2018 were evaluated. Results: Overall response rates (ORRs) were 2.6% (fulvestrant) and 41.9% (palbociclib-fulvestrant) (p<0.001), and clinical benefit rates (CBRs) were 23.1% and 61.3% (p=0.002), respectively. The palbociclib-fulvestrant group had significantly higher CBR and PFS (hazard ratio(HR):0.272, 95% confidence interval(95CI):0.128-0.574 for PFS). Grade 3/4 neutropenia occurred in 80.6% of the palbociclib-fulvestrant group, while febrile neutropenia was not detected. Conclusion: Japanese ER+/HER2− metastatic breast cancer patients tolerated palbociclib-fulvestrant, with significantly improved clinical outcomes.